Literature DB >> 15546236

Cervical cancer in the asian pacific-epidemiology, screening and treatment.

Malcolm A Moore1, Kazuo Tajima.   

Abstract

Squamous cell carcinoma (SCC) of the cervix continues to be a major problem in many areas of the Asian-Pacific, particularly in the Indian subcontinent and Papua New Guinea, and to a lesser extent in South-East Asia, Korea and Mongolia. In contrast, levels in the developed countries of the region are low, as is also the case for the Muslim countries of Western Asia, and mainland China. Incidence generally mirrora associated mortality, although with some exceptions reflecting facilities and infrastructure for early detection. Over the last 25 years there has been a marked decrease in incidence rates across most of the Asian Pacific, although less pronounced in India than elsewhere, and there are exceptions where the incidence is on the increase. The predominant risk factor is well established to be persistent infection with a high risk 'oncogenic' type of human papilloma virus (HPV), along with multiple partners, other sexually transmitted diseases and smoking. Consumption of vegetables, in contrast, appears to be protective. Hormonal factors may also play some role. Modifying factors may either impact on neoplasia by directly influencing the processes underlying carcinogenesis, or indirectly by affecting persistence of viral infections. For primary prevention, avoidance of repeated infections and smoking, as well as a high antioxidant intake may be beneficial. Vaccines against HPV also have promise for the future, but a better understanding of the mechanisms underlying spontaneous clearance of both infection and cervical intraepithelial neoplasia (CIN) of different grades is also essential for optimal intervention. For screening, the choice of whether the PAP smear, HPV testing or some form of visual inspection are utilized depends on the resources which are available, all approaches having their own advantages and disadvantages, but with similar sensitivity and specificity. One complication is the increase in adenocarcinoma of the cervix which has been reported in some countries, for which risk factors and most effective screening may differ from the SCC case. A focus on high risk groups like sex workers might be warranted where financial and technical support are limited. If cervical intraepithelial neoplasias are detected then cryotherapy or the loop electrosurgical excision procedure (LEEP) are effective for their removal. Control of cancer of the cervix, however, demands that a comprehensive approach to screening and management is adopted, necessitating major training of personnel and provision of appropriate resources.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546236

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Pattern of presentation of cervical carcinoma at Nuclear Institute of Medicine and Radiotherapy, Pakistan.

Authors:  Nousheen Aziz; Sajida Yousfani
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

2.  Associated factors with cervical pre-malignant lesions among the married fisher women community at Sadras, Tamil Nadu.

Authors:  Sornam Ganesan; Vasantha N Subbiah; Jothi Clara J Michael
Journal:  Asia Pac J Oncol Nurs       Date:  2015 Jan-Mar

3.  Amplification and up-regulation of MIR30D was associated with disease progression of cervical squamous cell carcinomas.

Authors:  You Zhou; Yinghua Hao; Yuxia Li; Ruizhen Li; Ruifang Wu; Shubin Wang; Zhengyu Fang
Journal:  BMC Cancer       Date:  2017-03-29       Impact factor: 4.430

4.  Determination and evaluation of HR-HPV genotype in different communities of Bihar, India.

Authors:  Akhtar Parwez; Sunit Singh; Rahul Kumar; Roushan Kumari; Vikas Kumar; Vidyut Prakash; Mohammad Ali
Journal:  Int J Health Sci (Qassim)       Date:  2022 Sep-Oct

5.  The burden of cervical cancer in China.

Authors:  Xiu Shen; Yiquan Cheng; Fupeng Ren; Zhilong Shi
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.